Dilaudid and Taltz drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Dilaudid (hydromorphone hydrochloride) and Taltz (ixekizumab). Common drug interactions include injection site pain among females and drug intolerance among males.

The phase IV clinical study analyzes what interactions people have when they take Dilaudid and Taltz. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Dilaudid?

Dilaudid has active ingredients of hydromorphone hydrochloride. It is often used in pain. eHealthMe is studying from 96,466 Dilaudid users. Check the latest studies of Dilaudid.

What is Taltz?

Taltz has active ingredients of ixekizumab. eHealthMe is studying from 29,777 Taltz users. Check the latest studies of Taltz.

On Jul, 17, 2026

12 people who take Dilaudid and Taltz together, and have interactions are studied.

What are the common drug interactions of Dilaudid and Taltz, by gender? *:

female:

Injection site pain
Injection site pruritus (severe itching at injection site)
Injection site swelling
Injection site urticaria (rash of round, red welts on the skin at injection site)
Injection site warmth
Pharyngeal neoplasm (pharyngeal tumour)
Pharyngeal oedema (abnormal accumulation of fluid in the cavities and intercellular spaces of the pharyngeal)
Swelling
Urticaria (rash of round, red welts on the skin that itch intensely)
Alopecia (absence of hair from areas of the body)

male:

Drug intolerance (drug sensitivity)
Eyelid oedema (eyelids are swollen and contain excessive fluid)
Face oedema (swelling of face)
Malaise (a feeling of general discomfort or uneasiness)
Nausea (feeling of having an urge to vomit)
Psoriasis (immune-mediated disease that affects the skin)

What are the common drug interactions of Dilaudid and Taltz, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Abdominal pain
Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)

30-39:

n/a

40-49:

Injection site urticaria (rash of round, red welts on the skin at injection site)
Injection site warmth
Pharyngeal neoplasm (pharyngeal tumour)
Pharyngeal oedema (abnormal accumulation of fluid in the cavities and intercellular spaces of the pharyngeal)
Swelling
Urticaria (rash of round, red welts on the skin that itch intensely)
Basal cell carcinoma (a skin cancer, it rarely metastasizes or kills)
Skin cancer
Squamous cell carcinoma (a cancer of a kind of epithelial cell)
Blood pressure increased

50-59:

Altered state of consciousness (altered state of mind)
Respiratory failure (inadequate gas exchange by the respiratory system)
Stupor (lack of critical cognitive function and level of consciousness)

60+:

n/a

What are the existing conditions these people have? *

Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 6 people, 50.00%
Psoriasis (immune-mediated disease that affects the skin): 5 people, 41.67%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 16.67%
Nausea (feeling of having an urge to vomit): 2 people, 16.67%
Joint Pain: 2 people, 16.67%
Fluid Retention (an abnormal accumulation of fluid in the blood): 1 person, 8.33%
Diarrhea: 1 person, 8.33%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Dilaudid and Taltz?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously